Minerva Neurosciences' NewcelX Appoints Expert Neurologist to Enhance Scientific Advisory Board

NewcelX Strengthens Scientific Advisory Board with Neurologist Expertise

On November 6, 2025, NewcelX Ltd., a biotechnology firm based in Zurich, Switzerland, announces the appointment of Professor Tamir Ben-Hur to its Scientific Advisory Board. Renowned for his work in neuroimmunology and stem-cell regenerative medicine, Professor Ben-Hur is affiliated with Hadassah University Medical Center and the Hebrew University of Jerusalem. His addition to the advisory board signifies a strategic enhancement that aligns with NewcelX’s commitment to pioneering innovative therapies for neurodegenerative diseases. Ben-Hur's extensive clinical background positions him to contribute significantly to the company's mission of integrating cell therapy with cutting-edge central nervous system (CNS) drugs, potentially transforming patient care on a global scale.

Professor Ben-Hur expresses enthusiasm about joining NewcelX, particularly in light of its ambition to develop groundbreaking treatments that address the underlying causes of conditions such as amyotrophic lateral sclerosis (ALS) and Type 1 diabetes. His expertise in combining neuroimmunology with regenerative approaches aligns seamlessly with NewcelX’s focus on scalable solutions for complex diseases. As the company looks to leverage advancements in both stem-cell technologies and neuroscience, Ben-Hur's insights are expected to guide the development of therapies that could significantly improve patient outcomes. His role on the board reinforces NewcelX's strategy of building a robust scientific foundation, which is crucial for driving innovation in the highly competitive biotech landscape.

In addition to Ben-Hur's appointment, NewcelX’s Chief Scientific Officer, Professor Michel Revel, emphasizes the importance of integrating clinical experience into the company’s research and development efforts. The collaboration between NewcelX and its strategic partners, including Kadimastem Ltd. and NLS Pharmaceutic Ltd., enhances its capabilities in delivering effective therapies. This merger combines advanced stem-cell platforms with expertise in CNS therapeutics, positioning NewcelX to explore novel approaches in treating neurodegenerative and metabolic diseases. The company’s integrated platform operates from Ness Ziona, Israel, and serves as a testament to NewcelX’s commitment to scientific integrity and innovation.

As NewcelX continues to advance its mission in the biotech sector, the appointment of Professor Ben-Hur marks a pivotal development in its strategic initiatives. His involvement is not only a reflection of the company’s dedication to enhancing its scientific advisory framework but also a proactive step towards realizing its vision for transformative therapies that hold the potential to dramatically impact patient lives.